

Press Release

For immediate release

OUELH'S JOINT VENTURE IS THE FIRST MYANMAR PRIVATE HOSPITAL GROUP TO PROCURE SINOPHARM COVID-19 VACCINE

- COVID-19 vaccine from Sinopharm ("**Sinopharm vaccine**"), procured by Pun Hlaing Hospitals, has arrived in Myanmar today
- Pun Hlaing Hospitals is the first private hospital group in Myanmar to:
 - Procure COVID-19 vaccine directly from Sinopharm
 - Receive approval from the Myanmar's Ministry of Health and Food & Drug Administration to import up to 400,000 doses of Sinopharm vaccine, based on the World Health Organisation Emergency Use Listing
- Pun Hlaing Hospitals repositioned its business to help alleviate the COVID-19 situation within its community
 - First private hospital group in Myanmar to be permitted by the Myanmar's National Central Committee for COVID-19 Protection, Control and Treatment to test, treat and care for COVID-19 patients
 - Set up four vaccination centres across Myanmar with the capacity to inoculate up to 10,000 people daily

Singapore, 18 November 2021 – OUE Lippo Healthcare Limited ("**OUELH**" or the "**Company**") and together with its subsidiaries, the "**Group**") announced that its Myanmar hospital joint venture with First Myanmar Investment Public Company Limited, Yoma Siloam Hospital Pun Hlaing Limited ("**Pun Hlaing Hospitals**" or "**PHH**"), received its shipment of the Sinopharm vaccine procured from Sinopharm and its related entities ("**Sinopharm**") today.

This will be the first time that a private hospital group in Myanmar has procured the Sinopharm vaccine directly from Sinopharm, as PHH is the first private hospital group to receive approval from Myanmar's Ministry of Health and Food & Drug Administration, to import and administer the Sinopharm vaccine.

Commenting on the latest development, Mr Yet Kum Meng, Chief Executive Officer of OUELH, said: *“The successful procurement of Sinopharm vaccine by PHH demonstrates the proactive repositioning of the business by its local management despite very dynamic and challenging circumstances in the country.”*

PHH repositioned to help alleviate the COVID-19 situation in Myanmar

Since the onset of the COVID-19 pandemic, PHH has steadfastly been building up its capacity to test, contain and treat COVID-19 patients. It is the first private hospital group in Myanmar to be permitted by the Myanmar’s National Central Committee for COVID-19 Protection, Control and Treatment to test, treat and care for COVID-19 patients.

“PHH continues to work tirelessly through the pandemic, with daily multidisciplinary clinical sessions to implement safe procedures in handling patients with infectious diseases,” remarked Dr Gershu Paul, Chief Executive Officer of PHH.

As part of its commitment to fight COVID-19 alongside its community, PHH set up four vaccination centres in Yangon, Mandalay and Taunggyi, which will be able to inoculate up to 10,000 people daily. To date, PHH has already administered more than 70,000 doses of Sinopharm vaccines, which were mainly procured under the vaccination programme launched by the Myanmar Chinese Chamber of Commerce.

The above is not expected to have a material impact on the earnings per share and net asset value per share of the Group for the current financial year ending 31 December 2021.

– END –

About OUE Lippo Healthcare Limited

OUE Lippo Healthcare Limited (“**OUELH**”) is a subsidiary company of OUE Limited. OUELH is a Pan-Asian healthcare group that owns, operates and invests in quality healthcare assets in high-growth Asian markets. Currently, OUELH owns 12 nursing homes in Japan; operates one hospital in Wuxi, China and has formed a 50:50 Joint Venture with China Merchants Group to develop and operate a hospital in Shenzhen, China as well as lease and operate a hospital in Changshu, Jiangsu Province, China; is in partnership with First Myanmar Investment to operate seven medical facilities in Myanmar; holds a 40% stake in First REIT Management Limited, which is the manager of First Real Estate Investment Trust (“**First REIT**”),

Singapore's first listed healthcare real estate investment trust); and holds a direct stake of approximately 15% in First REIT.

OUELH continually seeks to grow its healthcare businesses in Asia via its three-pronged strategy comprising strategic partnerships, asset-light business model and Pan-Asian expansion.

For media queries, please contact:

Hui Kheng CHIA
Managing Director, Citigate Dewe Rogerson
e. huikheng.chia@citigatedewerogerson.com

Melissa SIM
Senior Consultant, Citigate Dewe Rogerson
e. melissa.sim@citigatedewerogerson.com

For investor queries, please contact:

Shirley WONG
Investor Relations Manager
e. shirley.wong@ouelh.com

For the latest news from OUELH, visit www.ouelh.com

This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of the press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.